Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandro Balsa

Showing results (101-110 of 246) with videos related to

Pageof 25
Sort By:
Trials|September 2, 2020
Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA)Dalifer Freites-Núñez, Athan Baillet, Luis Rodriguez-Rodriguez, et al.
British Journal of Clinical Pharmacology|September 6, 2019
Biosimilar and interchangeable: Inseparable scientific concepts?Fernando de Mora, Alejandro Balsa, María Cornide-Santos, et al.
Seminars in Arthritis and Rheumatism|August 4, 2019
Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failureAna Martínez Feito, Chamaida Plasencia-Rodríguez, Victoria Navarro-Compán, et al.
Clinical Rheumatology|November 8, 2018
The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitorsAna Martínez-Feito, Chamaida Plasencia-Rodríguez, Victoria Navarro-Compán, et al.
Arthritis Research & Therapy|April 8, 2010
Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factorAlejandro Balsa, Arancha Cabezón, Gisela Orozco, et al.
International Journal of Environmental Research and Public Health|October 14, 2022
Medication Non-Adherence in Rheumatology, Oncology and Cardiology: A Review of the Literature of Risk Factors and Potential InterventionsVicente F Gil-Guillen, Alejandro Balsa, Beatriz Bernárdez, et al.
Clinical and Experimental Rheumatology|November 15, 2022
A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identificationMarta Novella-Navarro, Virginia Ruiz-Esquide, Gabriela Torres-Ortiz, et al.
Seminars in Arthritis and Rheumatism|October 9, 2023
Teleconsultation in rheumatology: A literature review and opinion paperJérôme Avouac, Hubert Marotte, Alejandro Balsa, et al.
Clinical and Experimental Rheumatology|May 17, 2022
Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitorsBorja Hernández-Breijo, Marta Novella-Navarro, Fernanda Genre, et al.
Rheumatology (Oxford, England)|February 6, 2024
Circulating Tfh cells are differentially modified by abatacept or TNF blockers and predict treatment response in rheumatoid arthritisIrene Monjo-Henry, Mariela Uyaguari, Laura Nuño, et al.
Pageof 25

Showing results (101-110 of 246) with videos related to

Sort By:
Pageof 25
Trials|September 2, 2020
Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA)Dalifer Freites-Núñez, Athan Baillet, Luis Rodriguez-Rodriguez, et al.
British Journal of Clinical Pharmacology|September 6, 2019
Biosimilar and interchangeable: Inseparable scientific concepts?Fernando de Mora, Alejandro Balsa, María Cornide-Santos, et al.
Seminars in Arthritis and Rheumatism|August 4, 2019
Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failureAna Martínez Feito, Chamaida Plasencia-Rodríguez, Victoria Navarro-Compán, et al.
Clinical Rheumatology|November 8, 2018
The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitorsAna Martínez-Feito, Chamaida Plasencia-Rodríguez, Victoria Navarro-Compán, et al.
Arthritis Research & Therapy|April 8, 2010
Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factorAlejandro Balsa, Arancha Cabezón, Gisela Orozco, et al.
International Journal of Environmental Research and Public Health|October 14, 2022
Medication Non-Adherence in Rheumatology, Oncology and Cardiology: A Review of the Literature of Risk Factors and Potential InterventionsVicente F Gil-Guillen, Alejandro Balsa, Beatriz Bernárdez, et al.
Clinical and Experimental Rheumatology|November 15, 2022
A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identificationMarta Novella-Navarro, Virginia Ruiz-Esquide, Gabriela Torres-Ortiz, et al.
Seminars in Arthritis and Rheumatism|October 9, 2023
Teleconsultation in rheumatology: A literature review and opinion paperJérôme Avouac, Hubert Marotte, Alejandro Balsa, et al.
Clinical and Experimental Rheumatology|May 17, 2022
Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitorsBorja Hernández-Breijo, Marta Novella-Navarro, Fernanda Genre, et al.
Rheumatology (Oxford, England)|February 6, 2024
Circulating Tfh cells are differentially modified by abatacept or TNF blockers and predict treatment response in rheumatoid arthritisIrene Monjo-Henry, Mariela Uyaguari, Laura Nuño, et al.
Pageof 25